arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HARVARD BIOSCIENCE INC

HBIO
$8.46 ▼ -0.21 (-2.48%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

HARVARD BIOSCIENCE INC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $375.5M
Dividend Yield —
Revenue Growth -8.1% ↗
Op. Margin -56.1% ↘
ROIC -96.8% ↘
FCF / Share $0.12 ↗
Trailing P/E —
Price / Book 27.6x
FCF Yield 1.5%
Debt / Equity 2.61
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$86.55M
↓ -8.1% —
Net Income Profit after all expenses
$-56.70M
↓ -357.1% —
Operating Margin Operating profit as % of sales
-56.1%
↓ -750.7% 5th
FCF / Share Free cash flow per share
$0.12
↑ +545.7% —
Long-Term Debt Long-term obligations
$35.87M
↓ -2.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
19
Financial Health ↑
18
Cash Quality ↑
19

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters